In a complaint filed March 18 in federal court in Washington , Mylan said it and other generic-drug makers should be allowed to enter the market as soon as a patent expires. Ranbaxy declined to comment on the lawsuit in an e-mail statement.
Mylan Sues US FDA to Block Ranbaxy's Sale of Lipitor Copy - Bloomberg
Check out underwear elastic products.
Ranbaxy, 64 percent owned by Tokyo-based Daiichi Sankyo Co., fell the most in a month in Mumbai on speculation that Mylan’s move may hamper its plan to start selling the medicine in the world’s largest drug market in November. The company has said it is entitled to 180 days of marketing exclusivity as a reward for being the first to challenge the Lipitor patents.Find elastic tapes and related product listing.
Ranbaxy, 64 percent owned by Tokyo-based Daiichi Sankyo Co., fell the most in a month in Mumbai on speculation that Mylan’s move may hamper its plan to start selling the medicine in the world’s largest drug market in November. The company has said it is entitled to 180 days of marketing exclusivity as a reward for being the first to challenge the Lipitor patents. “It is the first time someone is openly challenging Ranbaxy’s exclusivity for Lipitor,” Bino Pathiparampil, a Mumbai-based analyst at India Infoline Ltd., said. “It is incrementally negative for sure” for Ranbaxy.Find elastic tapes and related product listing.
Mylan Sues US FDA to Block Ranbaxy's Sale of Lipitor Copy - Bloomberg
Leave a comment